VEGFB and diabetic kidney disease: Concomitantly, it appears that either too much or too little of VEGFA can lead to pathological changes in the kidney.39 Interestingly, inhibition of VEGFB signalling in experimental DKD models appears to protect against DKD—via non‐angiogenic mechanisms—by ameliorating renal lipotoxicity and thereby reducing pathological changes in the kidney, sensitizing podocytes to insulin and preventing renal dysfunction.40